Form 8-K - Current report:
SEC Accession No. 0001437749-25-002160
Filing Date
2025-01-29
Accepted
2025-01-29 17:10:57
Documents
23
Period of Report
2025-01-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20250128_8k.htm   iXBRL 8-K 50952
2 EXHIBIT 4.3 ex_771257.htm EX-4.3 108903
3 EXHIBIT 4.4 ex_771258.htm EX-4.4 109167
4 EXHIBIT 5.1 ex_771585.htm EX-5.1 7907
5 EXHIBIT 10.2 ex_771259.htm EX-10.2 192807
6 EXHIBIT 10.3 ex_771260.htm EX-10.3 64986
7 EXHIBIT 99.1 ex_771586.htm EX-99.1 18565
12 image1.jpg GRAPHIC 3334
13 image2.jpg GRAPHIC 7571
14 image3.jpg GRAPHIC 5592
  Complete submission text file 0001437749-25-002160.txt   853522

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20250127.xsd EX-101.SCH 3911
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20250127_def.xml EX-101.DEF 13856
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20250127_lab.xml EX-101.LAB 18278
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20250127_pre.xml EX-101.PRE 13888
25 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20250128_8k_htm.xml XML 4969
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 25570280
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)